• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Efficacy and effectiveness of first-line oral medications in MS

May 21, 2015
Recommend to a Colleague print
 

REVIEWER: Mark S. Freedman, HBSc, MSc, MD, CSPQ, FANA, FAAN, FRCPC, Professor of Medicine (Neurology), University of Ottawa, Canada

Efficacy
NNT analysis
Safety
Natalizumab discontinuation studies
NeuroSens Survey on first-line orals

It takes 30 seconds
or login using your email address

Please enter the email address that you registered the newsletter with

TOPICS: AAN 2015, MS
Recommend to a Colleague

Related Posts

  • Putting biomarkers into practice
    March 8, 2023
  • CNS effects of Wegovy (semaglutide)
    February 28, 2023
  • CLINICAL CASES IN MS – A YOUNG WOMAN WITH BREAKTHROUGH DISEASE ON FINGOLIMOD
    February 22, 2023
  • Putting shared decision-making into practice
    February 16, 2023
  • CLINICAL CASES IN MS – AN OLDER PATIENT WITH STABLE DISEASE
    February 9, 2023
Go back to home page

Browse by Topic

MS (336)
AD (82)
PD (78)
COVID-19 (58)
PREVIOUS CONGRESSES (37)
DEPRESSION (36)
MIGRAINE (26)
SCHIZOPHRENIA (25)
STROKE (22)
EPILEPSY (22)
BIOMARKERS IN MS (15)
ECTRIMS 2015 (13)
Library (13)
AAN 2015 (11)
ECTRIMS 2014 (10)
ECTRIMS 2021 (10)
DEMENTIA (10)
ECTRIMS 2019 (10)
CLINICAL CASES IN MS (9)
AAN 2014 (9)
MS SEQUENCING (9)
ECTRIMS 2013 (9)
ECTRIMS 2018 (9)
AAN 2013 (9)
PSYCHIATRY (8)
ACTRIMS-ECTRIMS 2020 (7)
AAN 2019 (7)
ECTRIMS 2017 (6)
ECTRIMS 2022 (6)
AAN 2021 (6)
CHARCOT 2013 (6)
AAN 2022 (5)
BIPOLAR (5)
ECTRIMS 2016 (5)
ANXIETY (5)
CCSVI (5)
EAN 2015 (4)
NeuroSound (4)
BPD (4)
ENS 2013 (3)
AAN 2017 (3)
AAN 2020 (3)
EAN 2022 (3)
PAIN (3)
EAN 2020 (2)
NEW DRUGS (2)
SLEEP (2)
AAN 2018 (2)
SPECIAL REPORT (2)
APA 2014 (2)
ACTRIMS 2022 (1)
LUMBAR PUNCTURE (1)
EAN 2021 (1)
WEST NILE (1)
INSOMNIA (1)
GUIDELINES (1)
TSC (1)
AAN 2016 (1)
APA 2016 (1)
SEIZURE (1)
hATTR (1)
Dravet syndrome (1)
CIDP (1)
CONCUSSION (1)
ADDICTION (1)
ALS (1)
EAN 2019 (1)
LGS (1)
ACTRIMS 2023 (1)
EAN 2016 (0)
ECTRIMS 2020 (0)
BIOMARKERS (0)
View all Topics

Popular Posts

  • Progression independent of relapses (PIRA) in MS posted on November 21, 2019
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • CNS effects of Wegovy (semaglutide) posted on February 28, 2023
Copyright 2023 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions